Disseminated intravascular coagulation classification: Difference between revisions
No edit summary |
|||
| Line 36: | Line 36: | ||
Disseminated intravascular coagulation may be classified according to the degree of fibrinolytic activation into the following subtypes/groups<ref name="pmid25520834">{{cite journal |vauthors=Asakura H |title=Classifying types of disseminated intravascular coagulation: clinical and animal models |journal=J Intensive Care |volume=2 |issue=1 |pages=20 |date=2014 |pmid=25520834 |pmc=4267600 |doi=10.1186/2052-0492-2-20 |url=}}</ref>: | Disseminated intravascular coagulation may be classified according to the degree of fibrinolytic activation into the following subtypes/groups<ref name="pmid25520834">{{cite journal |vauthors=Asakura H |title=Classifying types of disseminated intravascular coagulation: clinical and animal models |journal=J Intensive Care |volume=2 |issue=1 |pages=20 |date=2014 |pmid=25520834 |pmc=4267600 |doi=10.1186/2052-0492-2-20 |url=}}</ref>: | ||
===Suppressed-fibrinolytic-type DIC (DIC with suppressed fibrinolysis) | === Suppressed-fibrinolytic-type DIC (DIC with suppressed fibrinolysis) <ref name="pmid11395595">{{cite journal |vauthors=Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S |title=An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation |journal=Crit. Care Med. |volume=29 |issue=6 |pages=1164–8 |date=June 2001 |pmid=11395595 |doi= |url=}}</ref><ref name="pmid1689102">{{cite journal |vauthors=Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A |title=Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders |journal=Am. J. Hematol. |volume=33 |issue=2 |pages=90–5 |date=February 1990 |pmid=1689102 |doi= |url=}}</ref><ref name="pmid7865691">{{cite journal |vauthors=Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T |title=Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers |journal=Blood Coagul. Fibrinolysis |volume=5 |issue=5 |pages=829–32 |date=October 1994 |pmid=7865691 |doi= |url=}}</ref><ref name="pmid1899963">{{cite journal |vauthors=Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T |title=Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation |journal=Am. J. Hematol. |volume=36 |issue=3 |pages=176–83 |date=March 1991 |pmid=1899963 |doi= |url=}}</ref> === | ||
* Severe coagulation activation | * Severe coagulation activation | ||
* Mild fibrinolytic activation | * Mild fibrinolytic activation | ||
Revision as of 17:18, 22 August 2018
|
Disseminated intravascular coagulation Microchapters |
|
Differentiating Disseminated intravascular coagulation from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Disseminated intravascular coagulation classification On the Web |
|
American Roentgen Ray Society Images of Disseminated intravascular coagulation classification |
|
FDA on Disseminated intravascular coagulation classification |
|
CDC on Disseminated intravascular coagulation classification |
|
Disseminated intravascular coagulation classification in the news |
|
Blogs on Disseminated intravascular coagulation classification |
|
Directions to Hospitals Treating Disseminated intravascular coagulation |
|
Risk calculators and risk factors for Disseminated intravascular coagulation classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
Disseminated intravascular coagulation may be classified according to the degree of fibrinolytic activation into the following subtypes/groups[1]:
Suppressed-fibrinolytic-type DIC (DIC with suppressed fibrinolysis) [2][3][4][5]
- Severe coagulation activation
- Mild fibrinolytic activation
- Seen in sepsis mostly
- Mild bleeding complications
- Elevated thrombin-antithrombin complex (TAT) , a coagulation activation marker
- Mildy elevated plasmin-α2 plasmin inhibitor complex (PIC), a fibrinolysis activation marker [6, 15–17]
- Mildly elevated Fibrin/fibrinogen degradation products (FDPs) and D-dimers
- Normal or only slightly decreased α2 plasmin inhibitor (α2PI)
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
References
- ↑ Asakura H (2014). "Classifying types of disseminated intravascular coagulation: clinical and animal models". J Intensive Care. 2 (1): 20. doi:10.1186/2052-0492-2-20. PMC 4267600. PMID 25520834.
- ↑ Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S (June 2001). "An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation". Crit. Care Med. 29 (6): 1164–8. PMID 11395595.
- ↑ Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A (February 1990). "Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders". Am. J. Hematol. 33 (2): 90–5. PMID 1689102.
- ↑ Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T (October 1994). "Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers". Blood Coagul. Fibrinolysis. 5 (5): 829–32. PMID 7865691.
- ↑ Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T (March 1991). "Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation". Am. J. Hematol. 36 (3): 176–83. PMID 1899963.